Department of Cardiac Surgery, Mazzini Hospital, Teramo, Italy.
Ann Thorac Surg. 2012 Oct;94(4):1185-90. doi: 10.1016/j.athoracsur.2012.05.015. Epub 2012 Jun 28.
The aim of this retrospective study was to compare the early and midterm clinical outcomes of aortic root replacement in elderly patients receiving the Freestyle stentless bioprosthesis (FSB) (Medtronic Inc, Minneapolis, MN) with younger patients receiving a mechanical valve conduit.
From January 2001 to December 2010, 185 consecutive patients underwent aortic root replacement. Of these, 79 (43%) patients received the Freestyle bioroot (Medtronic Inc, Minneapolis, MN) (group F) and 106 (57%) patients received a mechanical valve conduit (group M). Target endpoints were 30-day mortality, 5-year survival, 5-year freedom from cardiac death, and 5-year freedom from major adverse valve-related and cardiovascular events (MAVCE) (cardiac death, cerebrovascular accident, myocardial infarction, heart failure, valve prosthesis dysfunction requiring reoperation, and thromboembolic and hemorrhagic events). A propensity score model was built to adjust the results according to preoperative and operative characteristics of both groups.
Thirty-day mortality was similar in both groups (F group, 2.5% versus M group, 5.7%; p=0.407). Unadjusted analysis showed no differences between groups, whereas adjusted analysis showed a significantly higher 5-year freedom from cardiac death and MAVCE in group F (group F, 98.6±1.9 versus group M, 88.0%±3.0%; p=0.038; group F, 97.4%±2.6% versus group M, 81.2%±3.6%; p=0.010). Multivariate analysis confirmed a significantly higher risk for 5-year MAVCE in patients who did not undergo implantation with the Freestyle bioprosthesis (hazard ratio [HR], 6.87; 95% confidence limit [CL], 1.43-15.09; p=0.016).
In elderly patients, the FSB seems to be as safe as mechanical composite grafts in the perioperative period but results in superior freedom from MAVCE at 5 years postoperatively.
本回顾性研究的目的是比较在老年患者中使用 Freestyle 无支架生物瓣(FSB)(美敦力公司,明尼苏达州明尼阿波利斯)与年轻患者使用机械瓣膜导管进行主动脉根部置换的早期和中期临床结果。
从 2001 年 1 月至 2010 年 12 月,185 例连续患者接受了主动脉根部置换。其中,79 例(43%)患者接受了 Freestyle bioroot(美敦力公司,明尼苏达州明尼阿波利斯)(F 组),106 例(57%)患者接受了机械瓣膜导管(M 组)。目标终点为 30 天死亡率、5 年生存率、5 年无心脏死亡、5 年无主要不良瓣膜相关和心血管事件(MAVCE)(心脏死亡、脑卒、心肌梗死、心力衰竭、需要再次手术的瓣膜假体功能障碍以及血栓栓塞和出血事件)。建立倾向评分模型,根据两组的术前和手术特点调整结果。
两组 30 天死亡率相似(F 组,2.5%比 M 组,5.7%;p=0.407)。未调整分析两组之间无差异,而调整分析显示 F 组 5 年无心脏死亡和 MAVCE 明显更高(F 组,98.6±1.9 比 M 组,88.0%±3.0%;p=0.038;F 组,97.4%±2.6%比 M 组,81.2%±3.6%;p=0.010)。多变量分析证实,未植入 Freestyle 生物瓣的患者 5 年 MAVCE 的风险显著增加(风险比[HR],6.87;95%置信区间[CL],1.43-15.09;p=0.016)。
在老年患者中,FSB 在围手术期与机械复合移植物一样安全,但在术后 5 年时可获得更高的 MAVCE 无事件率。